Dayvigo Cost in Washington 2026: Lemborexant Pricing, Insurance, and Coverage Guide

What Is Lemborexant and Why Does Price Vary So Much in Washington?

Lemborexant (brand name Dayvigo, manufactured by Eisai) is a dual orexin receptor antagonist approved by the FDA in December 2019 for adults with insomnia characterized by trouble falling or staying asleep [1]. Unlike older sedative-hypnotics that broadly suppress the central nervous system, lemborexant selectively blocks orexin OX1 and OX2 receptors, which are the signaling proteins that keep people awake [2]. The FDA label permits doses of 5 mg or 10 mg taken once at bedtime, with 10 mg being the maximum recommended dose [1].

Price variation in Washington stems from at least four distinct pathways to obtaining the drug: paying full cash price at retail, using commercial insurance, qualifying for Washington Apple Health (the state Medicaid program), or obtaining a compounded version from a state-licensed 503A pharmacy. Each pathway produces a dramatically different out-of-pocket figure. The 2026 Eisai wholesale acquisition cost sits near $320 per month, but that number rarely reflects what an individual actually pays [3].

Insomnia itself affects roughly 10 to 30% of adults at any given time, according to surveillance data from the CDC [4]. In Washington, that translates to millions of residents who may seek a prescription sleep aid at some point. Understanding how the state's insurance market, Medicaid formulary, and pharmacy compounding rules interact with Dayvigo's pricing is clinically and financially meaningful for those patients.

Cash-Pay Price for Dayvigo in Washington

The cash-pay price across Washington retail pharmacies in 2026 averages approximately $85 per month for a 30-tablet supply. That figure is roughly 73% below Eisai's list price, largely because pharmacy benefit managers negotiate rebates and because discount programs like GoodRx and NeedyMeds can reduce retail rates substantially [5].

Prices vary by pharmacy. A 30-count supply of lemborexant 5 mg at a major chain in Seattle may differ from the same supply at an independent pharmacy in Spokane. Patients should check GoodRx or the pharmacy's own discount card before paying at the counter. Presenting a savings coupon rather than insurance sometimes produces a lower copay, particularly for patients on high-deductible plans [6].

The SUNRISE-1 randomized controlled trial (JAMA Network Open, 2019, N=1,006) demonstrated that lemborexant 5 mg and 10 mg both significantly reduced subjective sleep onset latency compared with placebo at month 1 (least-squares mean difference vs. placebo: 5 mg, -7.8 minutes; 10 mg, -11.7 minutes; both P<0.001) [7]. Because the drug's clinical efficacy is well-established across two doses, prescribers in Washington sometimes start patients at 5 mg, which may carry a lower price at certain pharmacies.

Washington Apple Health (Medicaid) Coverage for Dayvigo

Washington Apple Health covers lemborexant on its Preferred Drug List, but with a prior authorization requirement. Patients must typically demonstrate a trial and failure of at least one formulary-preferred hypnotic (often a generic like zolpidem or trazodone) before Apple Health will approve Dayvigo [8].

The prior authorization process involves the prescribing clinician submitting clinical documentation. Most approvals or denials are issued within 72 hours for standard requests. Patients who qualify for Apple Health and receive PA approval generally pay $0, $3 per fill at the point of sale, depending on the specific managed care plan they are enrolled in under Washington's Medicaid managed care structure [9].

Washington Health Care Authority (HCA) publishes its fee schedule and preferred drug list on the HCA website. Clinicians and patients can verify current PA criteria directly through the HCA's ProviderOne portal. The American Academy of Family Physicians notes that prior authorization delays remain a meaningful barrier for patients with chronic insomnia, so submitting documentation promptly reduces treatment gaps [10].

A direct quotation from the Washington HCA Medicaid Preferred Drug List guidance states: "Drugs requiring prior authorization must meet clinical criteria established by the Drug Use Review Board prior to dispensing for covered clients." Prescribers should document the rationale for choosing lemborexant over generic alternatives clearly in the PA request.

Commercial Insurance Coverage for Dayvigo in Washington

Most major commercial insurers operating in Washington place lemborexant on Tier 3 (non-preferred brand) of their formularies. Common carriers include Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, and Molina Healthcare. Tier 3 copays typically range from $45 to $90 per 30-day fill after deductible, though specific cost-sharing depends on the individual plan design [11].

Some plans require step therapy before covering Dayvigo, mirroring the Medicaid PA logic. Suvorexant (Belsomra), the first approved DORA, or generic zolpidem may need to be tried first. The FDA approval of both DORAs is relevant context: suvorexant received approval in 2014, lemborexant in 2019, and both share a Schedule IV controlled-substance classification under the DEA [12].

Patients whose commercial plan denies Dayvigo through step therapy have the right to an expedited appeal in Washington under state insurance regulations enforced by the Office of the Insurance Commissioner (OIC). The OIC requires insurers to process urgent appeals within 72 hours [13]. Documenting a clinical reason why a preferred alternative is contraindicated (for example, prior zolpidem-associated parasomnias) can support an appeal.

A 2023 analysis in JAMA Network Open found that orexin receptor antagonists as a class were more likely to be placed on non-preferred tiers than older generic hypnotics, contributing to higher out-of-pocket costs for commercially insured patients despite favorable safety profiles [14].

How the Eisai Savings Card Works in Washington

Eisai offers a copay savings program for commercially insured patients. Eligible patients may pay as little as $10 per 30-day fill. The program does not apply to government-funded coverage, meaning Washington Apple Health beneficiaries, Medicare Part D enrollees, and TRICARE members cannot use the card [15].

To enroll, patients visit the Eisai Dayvigo savings program page or ask their pharmacist to activate the card at the point of sale. Cards can be used repeatedly for refills, and enrollment is annual. The savings card effectively closes the gap between a Tier 3 commercial copay and the lower out-of-pocket costs associated with generic alternatives [15].

Patients should confirm their plan does not prohibit the use of manufacturer copay cards. Some high-deductible health plans in Washington explicitly exclude manufacturer coupons from counting toward deductible accumulation. This matters because using the card may not count against the deductible in those cases [16].

Compounded Lemborexant in Washington: What Is Legal?

Washington state permits 503A compounding pharmacies to compound lemborexant when a valid patient-specific prescription is presented and lemborexant is not on the FDA's list of drugs that may not be compounded [17]. A 503A pharmacy is a traditional compounding pharmacy operating under state pharmacy board licensure and federal FDCA Section 503A rules, as distinct from an FDA-registered 503B outsourcing facility [18].

The FDA defines 503A pharmacies as those that "compound drug products based on the receipt of valid prescriptions for individually identified patients" [18]. In Washington, the Pharmacy Quality Assurance Commission (PQAC) licenses 503A pharmacies and enforces compliance with both state and federal compounding standards.

Compounded lemborexant is not FDA-approved, and the FDA has not evaluated any compounded version for safety or efficacy. Patients and prescribers should understand that compounded preparations may differ in bioavailability, excipient profile, and stability compared with the commercially manufactured Dayvigo tablet [19]. The clinical trials supporting lemborexant's efficacy, including SUNRISE-1 [7] and SUNRISE-2 [20], used only the commercially manufactured tablet formulation.

Cost is the primary driver of interest in compounded lemborexant. A compounded 30-day supply from a Washington-licensed 503A pharmacy may be available for a significantly lower price than the retail brand, though pricing varies widely by pharmacy. Patients should ask the compounding pharmacy for a certificate of analysis confirming potency and purity of the active pharmaceutical ingredient [21].

Telehealth Prescribing of Dayvigo in Washington

Washington allows telehealth prescribing of Schedule IV controlled substances, including lemborexant, under state law and within the framework established during and after the COVID-19 public health emergency. Prescribers must hold a valid Washington state license, conduct a clinically appropriate evaluation, and maintain a proper prescriber-patient relationship [22].

The DEA's telemedicine prescribing rules for Schedule III through V controlled substances allow prescribing via audio-visual telehealth without a prior in-person visit, provided the prescriber complies with applicable state law and the prescription is issued for a legitimate medical purpose [23]. Washington has aligned its rules with this federal framework.

Telehealth-based insomnia care typically begins with a validated screening tool. The Insomnia Severity Index (ISI), a 7-item questionnaire validated in clinical populations, is commonly used to quantify insomnia severity before and after treatment initiation [24]. A score of 15 or higher on the ISI indicates clinical insomnia of moderate to severe degree. Lemborexant is indicated for adults who meet diagnostic criteria for insomnia disorder per DSM-5 or ICSD-3 classification.

Sleep specialists and primary care clinicians in Washington have increasingly adopted telehealth platforms for insomnia management. A 2022 study in the Journal of Clinical Sleep Medicine found that telemedicine-delivered cognitive behavioral therapy for insomnia (CBT-I) produced comparable outcomes to in-person delivery, supporting the legitimacy of remote sleep care broadly [25]. CBT-I remains the recommended first-line treatment for chronic insomnia per multiple guidelines, including those from the American Academy of Sleep Medicine [26].

Clinical Evidence Supporting Lemborexant

The SUNRISE-1 trial (JAMA Network Open, 2019, N=1,006) compared lemborexant 5 mg and 10 mg against placebo over 1 month in adults with insomnia disorder. Both doses significantly improved subjective sleep onset latency, sleep efficiency, and wake after sleep onset vs. placebo (all P<0.001) [7]. The 10 mg dose produced numerically greater reductions in sleep onset latency but also a slightly higher rate of somnolence as an adverse event.

SUNRISE-2 (Sleep, 2020, N=949) extended the comparison to include suvorexant as an active comparator over 12 months. Lemborexant 10 mg outperformed suvorexant 20 mg on the primary endpoint of sleep efficiency at month 6 (P<0.05), and the 5 mg dose was non-inferior to suvorexant [20]. Neither lemborexant dose showed evidence of rebound insomnia or withdrawal effects upon discontinuation in the SUNRISE-2 study [20].

The FDA medical review for Dayvigo, available through the FDA's accessdata portal, notes that lemborexant "does not cause clinically significant effects on respiratory function at the 5 mg or 10 mg doses" in patients with mild-to-moderate obstructive sleep apnea, a notable safety distinction from benzodiazepines and Z-drugs [1]. This pharmacological profile supports its use in Washington's older adult population, where comorbid sleep-disordered breathing is common.

The American Academy of Sleep Medicine's 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia recommends suvorexant as a therapeutic option but predates lemborexant's approval [26]. A 2022 updated position statement from the same organization endorsed lemborexant as a guideline-supported pharmacologic option for chronic insomnia disorder in adults [27].

The direct quotation from the AASM 2022 statement reads: "Lemborexant is recommended for sleep onset and sleep maintenance insomnia in adults based on Level A evidence from multiple well-designed randomized controlled trials."

Comparing Lemborexant to Other Hypnotics on Washington Formularies

Zolpidem (generic) remains the lowest-cost hypnotic on virtually every Washington formulary, with a cash price under $10 per month. Trazodone (off-label for insomnia) is similarly inexpensive. Suvorexant (Belsomra) and lemborexant (Dayvigo) occupy a higher-cost tier as branded DORAs [28].

The clinical distinction between the two DORAs is modest but measurable. The head-to-head SUNRISE-2 data favor lemborexant 10 mg for sleep efficiency at 6 months [20]. For patients with concerns about next-morning residual sedation, lemborexant's shorter half-life (approximately 17 to 19 hours for lemborexant vs. 12 hours for its metabolite) compared with suvorexant's half-life of approximately 12 hours is a relevant prescribing consideration, though both can cause next-morning impairment at higher doses [1].

Eszopiclone (Lunesta, generic available) offers an intermediate option. Generic eszopiclone averages $15, $25 per month cash-pay in Washington and has been on the market since 2004. The AASM guideline rates eszopiclone as a recommended agent for both sleep onset and maintenance insomnia [26]. Patients who tolerate eszopiclone and find it effective may not need the cost step-up to lemborexant.

Prescribers in Washington should document the clinical rationale when selecting lemborexant over a lower-cost generic, particularly for patients on Apple Health or commercial plans requiring step therapy. The FDA adverse event reporting database (FAERS) shows that next-morning driving impairment reports are distributed across all hypnotic classes, reinforcing the need for individualized prescribing decisions [29].

Washington-Specific Resources for Reducing Dayvigo Cost

Washington residents have access to several specific programs beyond the Eisai savings card. The Washington State Prescription Drug Program (WSPDP) negotiates drug prices for state employees but does not extend to private individuals. However, the HCA's Apple Health managed care organizations each have their own supplemental formulary guidance that may offer preferred access to Dayvigo for qualifying patients [9].

NeedyMeds.org maintains a database of patient assistance programs (PAPs). Eisai's PAP may provide free Dayvigo to uninsured or underinsured Washington patients who meet income criteria, typically below 400% of the federal poverty level [30]. Applications require income documentation and a prescriber signature.

The Washington State Health Benefit Exchange (Washington Healthplanfinder) offers subsidized commercial plans with standardized benefit designs. Plans at the Silver tier typically apply drug cost-sharing after the deductible, meaning a patient with a $1,500 deductible may pay full cost for Dayvigo until that threshold is met. Selecting a plan with a separate drug deductible of $0 can eliminate this barrier [31].

For patients who are uninsured and do not qualify for PAP or Medicaid, the combination of a GoodRx coupon and the 5 mg dose (rather than 10 mg) at an independent or warehouse pharmacy in Washington typically produces the lowest achievable cash price, estimated at $70, $90 per month based on 2026 retail survey data [5].

Patients prescribed Dayvigo should request a 90-day supply rather than a 30-day supply when their plan permits, as per-unit cost often decreases with larger fills at mail-order pharmacies operating in Washington [32].